Clinical Trial Update: Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated combining osimertinib with aspirin to overcome resistance to first-generation EGFR-TKIs in non-small cell lung cancer; the study is re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Aspirin (Aspirin)
• Osimertinib (osimertinib)

Snippet

Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Conditions: Non-Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV | Phase 2 | Status: COMPLETED